
October to December 2025
| Drug Name | Government Contribution Dollars | Prescriptions |
|---|---|---|
| PEMBROLIZUMAB | $172,004,909 | 20,211 |
| ELEXACAFTOR + TEZACAFTOR + IVACAFTOR (&) IVACAFTOR | $169,622,452 | 8,350 |
| DUPILUMAB | $155,874,774 | 90,912 |
| AFLIBERCEPT | $117,960,751 | 119,990 |
| NIVOLUMAB | $107,797,459 | 15,218 |
| SEMAGLUTIDE | $106,774,071 | 870,717 |
| UPADACITINIB | $91,130,149 | 61,750 |
| APIXABAN | $81,807,341 | 1,222,666 |
| DARATUMUMAB | $73,921,303 | 10,361 |
| DENOSUMAB | $63,804,126 | 337,905 |
| TAFAMIDIS | $61,298,491 | 6,120 |
| OCRELIZUMAB | $61,071,045 | 3,732 |
| Drug Name | Government Contribution Dollars | Prescriptions |
|---|---|---|
| ROSUVASTATIN | $40,732,053 | 4,332,132 |
| PANTOPRAZOLE | $30,173,445 | 2,909,018 |
| ATORVASTATIN | $30,215,301 | 2,853,284 |
| ESOMEPRAZOLE | $23,304,979 | 2,029,633 |
| ESCITALOPRAM | $9,510,693 | 1,669,186 |
| METFORMIN | $17,282,697 | 1,662,889 |
| SERTRALINE | $9,779,332 | 1,621,705 |
| PERINDOPRIL | $14,711,915 | 1,608,597 |
| CEFALEXIN | $8,704,817 | 1,302,530 |
| AMLODIPINE | $12,182,663 | 1,256,103 |
| APIXABAN | $81,807,341 | 1,222,666 |
| AMOXICILLIN | $5,798,574 | 1,174,339 |
| Contributor | Contribution Dollars |
|---|---|
| Australian Government | $5,381,246,308 |
| Patients | $854,059,745 |